Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00073476
Recruitment Status : Terminated
First Posted : November 24, 2003
Last Update Posted : June 22, 2006
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Condition or disease Intervention/treatment Phase
Stroke Drug: traxiprodil (CP-101,606) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.
Study Start Date : September 2003
Study Completion Date : February 2005



Primary Outcome Measures :
  1. No or minimal neurological deficit at last visit
  2. Marked neurological improvement at last visit

Secondary Outcome Measures :
  1. Modified Rankin scale at last visit
  2. Mortality
  3. Safety assessments


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion Criteria:

Treatment with t-PA (tissue plasminogen activator)

Premorbid modified rankin scale score of 2 or more


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00073476


Locations
Layout table for location information
United States, California
Pfizer Investigational Site
La Mesa, California, United States, 91942
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
United States, Indiana
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46804
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46805
United States, Kentucky
Pfizer Investigational Site
Louisville,, Kentucky, United States, 40202
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
United States, North Carolina
Pfizer Investigational Site
Salisbury, North Carolina, United States, 28144
United States, Ohio
Pfizer Investigational Site
Dayton, Ohio, United States, 45406
Pfizer Investigational Site
Dayton, Ohio, United States, 45408
Pfizer Investigational Site
Dayton, Ohio, United States, 45409
Pfizer Investigational Site
Dayton, Ohio, United States, 45415
United States, Pennsylvania
Pfizer Investigational Site
Allentown, Pennsylvania, United States, 18103
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19141
Estonia
Pfizer Investigational Site
Tartu, Estonia, 51014
Germany
Pfizer Investigational Site
Bad Neustadt, Germany, 97616
Pfizer Investigational Site
Freiburg, Germany, 79106
Pfizer Investigational Site
Leipzig, Germany, 04103
Pfizer Investigational Site
Luebeck, Germany, 23538
Hungary
Pfizer Investigational Site
Budapest, Hungary, H-1021
Pfizer Investigational Site
Gyor, Hungary, H-9023
Italy
Pfizer Investigational Site
Pavia, Italy, 27100
Pfizer Investigational Site
Perugia, Italy, 06126
Portugal
Pfizer Investigational Site
Coimbra, Portugal, Codex 3049
Pfizer Investigational Site
Lisboa, Portugal, 1600
Singapore
Pfizer Investigational Site
Singapore, Singapore, 169608
Pfizer Investigational Site
Singapore, Singapore, 308433
Spain
Pfizer Investigational Site
Santiago de Compostela, Galicia, Spain, 15706
Pfizer Investigational Site
Madrid, Spain, 28007
Pfizer Investigational Site
Madrid, Spain, 28034
Pfizer Investigational Site
Zaragoza, Spain, 50009
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00073476    
Other Study ID Numbers: A1611005
First Posted: November 24, 2003    Key Record Dates
Last Update Posted: June 22, 2006
Last Verified: June 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases